Stockscreener 앱 받기
6.28
5.02%
0.30
전일 마감가:
$5.98
열려 있는:
$5.98
하루 거래량:
59,267
Relative Volume:
0.09
시가총액:
$4.65M
수익:
$9.81M
순이익/손실:
$-26.16M
주가수익비율:
-0.162
EPS:
-38.77
순현금흐름:
$-17.45M
1주 성능:
-5.71%
1개월 성능:
-30.82%
6개월 성능:
-95.21%
1년 성능:
-97.46%
1일 변동 폭
$5.8638
$6.80
1주일 범위
$5.6447
$6.80
52주 변동 폭
$5.53
$725.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
명칭
Reshape Lifesciences Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
RSLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
6.28 | 3.00M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc 주식(RSLS)의 최신 뉴스
ReShape Lifesciences Delays 10-Q Filing - TipRanks
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
Reshape Lifesciences Inc Files For Mixed Shelf Offering Of Up To $50 MillionSEC Filing - marketscreener.com
ReShape Lifesciences Announces Reverse Stock Split - TipRanks
ReShape Lifesciences announces 1-for-25 reverse stock split By Investing.com - Investing.com Canada
ReShape Lifesciences (RSLS) Announces 1-for-25 Reverse Stock Split - GuruFocus
ReShape Lifesciences announces 1-for-25 reverse stock split - Investing.com Australia
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split - The Manila Times
ReShape Lifesciences Inc. Announces 1-for-25 Reverse Stock Split Effective May 9, 2025 - Nasdaq
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerALBT, NDOI, DNB, RSLS - The Malaysian Reserve
ReShape Lifesciences (RSLS) Secures Patent for Innovative Intrag - GuruFocus
ReShape Lifesciences (RSLS) Showcases Promising Diabetes Device at Neuromodulation Event | RSLS Stock News - GuruFocus
ReShape Lifesciences® Unveils Innovative Diabetes Neuromodulation Device Demonstrating Safe Glucose Modulation at Minnesota Neuromodulation Symposium - Nasdaq
ReShape Lifesciences® Presents Pre-clinical Data on Its - GlobeNewswire
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS - GlobeNewswire Inc.
The Psychology of ReShape Lifesciences Inc Inc. (RSLS) Price Performance: Understanding Market Sentiment - investchronicle.com
There is no way ReShape Lifesciences Inc (RSLS) can keep these numbers up - Sete News
Market Resilience: ReShape Lifesciences Inc (RSLS) Finishes Weak at 0.36, Down -0.85 - DWinneX
Checking in on ReShape Lifesciences Inc (RSLS) after recent insiders movement - knoxdaily.com
Closing Figures Unveiled: ReShape Lifesciences Inc (RSLS) Drop -12.17, Closes at 0.39 - DWinneX
ReShape Lifesciences amends asset purchase terms with Ninjour By Investing.com - Investing.com Nigeria
ReShape Lifesciences secures patent for intragastric balloon By Investing.com - Investing.com Canada
ReShape Lifesciences amends asset purchase terms with Ninjour - Investing.com
ReShape Lifesciences (RSLS) Advances with New Patent for Intraga - GuruFocus
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - The Manila Times
Revolutionary Weight Loss Tech: ReShape's New Patent Protects Self-Deflating Gastric Balloon Innovation - Stock Titan
ReShape Lifesciences Inc (RSLS)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Press Release Distribution & PR Platform - ACCESS Newswire
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - The Globe and Mail
Insider Sale Alert: ReShape Lifesciences Inc [RSLS] – Is it Time to sell? - knoxdaily.com
ReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technology - MSN
ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System - Investing.com India
ReShape Shares Soar After USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences secures patent for diabetes treatment By Investing.com - Investing.com South Africa
ReShape Lifesciences Gets USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences (RSLS) Gains on Diabetes Neuromodulation Patent News - GuruFocus
ReShape Lifesciences secures patent for diabetes treatment - Investing.com
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - The Manila Times
ReShape Lifesciences® Secures Patent for Innovative Vagal Neuromodulation Device to Treat Type 2 Diabetes with Enhanced Energy Efficiency - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for - GlobeNewswire
Top Midday Gainers - marketscreener.com
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Why Did ReShape Lifesciences Plunge 11.04%? Earnings Miss, Bearish Sentiment - AInvest
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop - Investing.com UK
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
12 Health Care Stocks Moving In Friday's Intraday SessionCeriBell (NASDAQ:CBLL), CEL-SCI (AMEX:CVM) - Benzinga
ReShape Lifesciences Reports 2024 Financial Results and Strategic Updates - TipRanks
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop By Investing.com - Investing.com South Africa
Reshape Lifesciences Inc (RSLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
0.22%
자본화:
|
볼륨(24시간):